UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Sells 65,218 Shares of IQVIA Holdings Inc. $IQV

Key Points

• UBS AM reduced its stake in IQVIA Holdings Inc. by 4.7%, selling 65,218 shares and owning 1,327,922 shares valued at approximately $234 million.
• Advisory ratings show a consensus of “Moderate Buy” for IQVIA, with target prices from various analysts ranging between $177 and $225.
• IQVIA reported quarterly earnings of $2.81 EPS, surpassing analyst expectations and projecting FY 2025 guidance of 11.750-12.050 EPS.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.7% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,327,922 shares of the medical research company's stock after selling 65,218 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.77% of IQVIA worth $234,113,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in IQV. Pacer Advisors Inc. boosted its holdings in shares of IQVIA by 5,036.1% during the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock valued at $153,681,000 after purchasing an additional 854,732 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after purchasing an additional 798,534 shares during the last quarter. Hawk Ridge Capital Management LP bought a new position in shares of IQVIA during the 1st quarter valued at about $77,096,000. Nuveen LLC bought a new position in shares of IQVIA during the 1st quarter valued at about $76,328,000. Finally, GAMMA Investing LLC boosted its holdings in shares of IQVIA by 27,448.4% during the 1st quarter. GAMMA Investing LLC now owns 387,331 shares of the medical research company's stock valued at $68,286,000 after purchasing an additional 385,925 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent research reports. Cowen restated a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Robert W. Baird upped their target price on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Citigroup restated a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Finally, UBS Group upped their target price on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $229.64.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Stock Performance

IQVIA stock opened at $190.48 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $248.03. The firm has a market capitalization of $32.38 billion, a P/E ratio of 27.57, a price-to-earnings-growth ratio of 2.02 and a beta of 1.32. The company's 50-day moving average is $181.94 and its 200 day moving average is $167.45.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the prior year, the company posted $2.64 EPS. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.